Cost Curve News - News - https://www.costcurvenews.com/blog/page/12/

A Congressional Examination of Pharm-to-Table Deals Offers Zero Surprises

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

6 months ago

Keep Reading

Cost Curve News

BMS and Pfizer Plant the Seed for an Eliquis Pharm-to-Table Program

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

6 months ago

Keep Reading

Cost Curve News

Trump Says Tariffs Are Coming Within Weeks, Prompting Next to No Reaction from Anyone

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

6 months ago

Keep Reading

Cost Curve News

More Evidence that 340B Is Siphoning Billions from the Government

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

6 months ago

Keep Reading

Cost Curve News

It’s Deadline Day: Trump’s First Drug-Related Executive Order Calls for Action on Middlemen and Importation

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

6 months ago

Keep Reading

Cost Curve News

Forget What Happened Last Week: PBM Reform Looks Very Much Alive

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

6 months ago

Keep Reading

Cost Curve News

The Tax/Medicaid Bill Puts Rural Hospitals on the Brink … What Does That Mean for 340B?

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

6 months ago

Keep Reading

Cost Curve News

Trump Says Pharma Tariffs May Be Pushed Back, But Could Be Enormous If/When They Do Arrive

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

6 months ago

Keep Reading

Cost Curve News

More on the Tax-Cuts-and-Medicaid-Cuts Bill, Including an Apex Analysis of a Biotech-Boosting R&D Tax Provision

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

6 months ago

Keep Reading

Cost Curve News

Drilling Into Last Week’s Legislative Action: How the New Law Impacts Rare-Disease Development

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

6 months ago

Keep Reading

A Congressional Examination of Pharm-to-Table Deals Offers Zero Surprises

BMS and Pfizer Plant the Seed for an Eliquis Pharm-to-Table Program

Trump Says Tariffs Are Coming Within Weeks, Prompting Next to No Reaction from Anyone

More Evidence that 340B Is Siphoning Billions from the Government

It’s Deadline Day: Trump’s First Drug-Related Executive Order Calls for Action on Middlemen and Importation

Forget What Happened Last Week: PBM Reform Looks Very Much Alive

The Tax/Medicaid Bill Puts Rural Hospitals on the Brink … What Does That Mean for 340B?

Trump Says Pharma Tariffs May Be Pushed Back, But Could Be Enormous If/When They Do Arrive

More on the Tax-Cuts-and-Medicaid-Cuts Bill, Including an Apex Analysis of a Biotech-Boosting R&D Tax Provision

Drilling Into Last Week’s Legislative Action: How the New Law Impacts Rare-Disease Development

Latest Posts

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

Empty Offices, Full Coffers: A Journalistic Expose Examines How PBMs Use Group Purchasing Organizations to Profit

The Most Interesting Drug Pricing News of the Year Is Flying Under the Radar

We’re Back at It. Here Are the Four Key Holiday Storylines to Get You Caught Up.

Popular

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

Empty Offices, Full Coffers: A Journalistic Expose Examines How PBMs Use Group Purchasing Organizations to Profit

The Most Interesting Drug Pricing News of the Year Is Flying Under the Radar

We’re Back at It. Here Are the Four Key Holiday Storylines to Get You Caught Up.

Happy Festivus! Cost Curve Readers Have Some Grievances They’d Like to Air.

Latest News

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

Subcribe To Newsletter